On January 3, 2024 ChemDiv Inc, a leading provider of drug discovery platforms and development solutions, reported a significant milestone in collaboration with Orionis Biosciences: the commencement of Phase I clinical trials for ORB-011, a cutting-edge attenuated, cis-targeted interferon immunotherapy compound (Press release, ChemDiv, JAN 3, 2024, View Source [SID1234638933]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ORB-011, a pioneering clinical candidate emerging from Orionis’ innovative A-Kine platform, is the culmination of rigorous research and development efforts facilitated by ChemDiv’s robust covalent and bifunctional chem-bio arsenal. Engineered to exhibit highly selective, targeted activation of tumor-antigen-presenting cDC1 dendritic cells, ORB-011 leverages ChemDiv’s expertise in warheads to optimize interferon’s therapeutic potential while mitigating broad systemic activity and associated toxicities characteristic of traditional cytokine therapies.
"We take immense pride in our support of Orionis Biosciences’ discovery and development, which has culminated in the advancement of ORB-011 into clinical trials," said ChemDiv’s CEO, Bill Farley. "This marks a significant step in harnessing intrinsic immunobiology pharmacologically, and we are excited about the potential impact it may have on revolutionizing cancer therapeutics."
The initiation of Phase I clinical trials for ORB-011 is a significant milestone, underscoring the transformative potential of ChemDiv and Orionis Biosciences synergistic research, pushing the boundaries of collaborative drug discovery to improve patient outcomes in the fight against cancer.